Canopy Growth vs Sichuan Kelun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Canopy Growth Corp (CGC)

Q3 202625 Jul – 23 Sep 2026

▲3▼2

Canopy's sales grow but US hopes stall and dilution forces reverse split

Sales growth and shrinking losses Canopy's quarterly revenue rose 13% to C$81.2 million, gross margin improved to 31%, and its adjusted EBITDA loss shrank 59%. Management still targets positive EBITDA this fiscal year. In plain terms, the business is losing less money and selling more, which supports the stock's value.
Shows the fundamental improvement that is the main positive force on CGC.
Debt cut, net cash, medical cannabis growth Canopy finished a major recapitalization that slashed debt and left it with about $131.3 million in net cash. Canadian medical cannabis revenue grew 27% and international medical grew 68%, led by Germany. Less debt and more cash make the company financially safer.
Highlights the balance-sheet repair and medical growth that reduce risk for CGC.
UK medical market entry Canopy signed a supply deal to sell four Canadian-grown medical cannabis strains in the United Kingdom through distributor GROW Group, under its Spectrum Therapeutics brand. This opens a new market for its products, which can add future revenue and supports the stock.
A concrete new distribution deal that expands demand for CGC's products.
US rescheduling stalls and heavy dilution US medical marijuana was rescheduled to Schedule III in April 2026, but broader recreational reforms that would help Canopy USA were left out, so the expected US boost has not materialized. Meanwhile, share count ballooned from 240 million to 423 million, and another $200 million ATM program could dilute holders further. More shares means each existing share is worth less.
Explains the two main forces keeping CGC's stock under $1 despite better sales.
Another reverse stock split to protect listing With shares back below $1, Canopy is asking shareholders on Sept. 25 to approve another reverse stock split, after a 2023 split was followed by an 80% drop. A reverse split is a sign the company has no better option and often signals underlying weakness, weighing on sentiment.
A new negative event that directly reflects the stock's listing pressure.

August 202625 Jul – 23 Sep 2026

▲3▼2

Canopy's sales grow but US hopes stall and dilution forces reverse split

Sales growth and shrinking losses Canopy's quarterly revenue rose 13% to C$81.2 million, gross margin improved to 31%, and its adjusted EBITDA loss shrank 59%. Management still targets positive EBITDA this fiscal year. In plain terms, the business is losing less money and selling more, which supports the stock's value.
Shows the fundamental improvement that is the main positive force on CGC.
Debt cut, net cash, medical cannabis growth Canopy finished a major recapitalization that slashed debt and left it with about $131.3 million in net cash. Canadian medical cannabis revenue grew 27% and international medical grew 68%, led by Germany. Less debt and more cash make the company financially safer.
Highlights the balance-sheet repair and medical growth that reduce risk for CGC.
UK medical market entry Canopy signed a supply deal to sell four Canadian-grown medical cannabis strains in the United Kingdom through distributor GROW Group, under its Spectrum Therapeutics brand. This opens a new market for its products, which can add future revenue and supports the stock.
A concrete new distribution deal that expands demand for CGC's products.
US rescheduling stalls and heavy dilution US medical marijuana was rescheduled to Schedule III in April 2026, but broader recreational reforms that would help Canopy USA were left out, so the expected US boost has not materialized. Meanwhile, share count ballooned from 240 million to 423 million, and another $200 million ATM program could dilute holders further. More shares means each existing share is worth less.
Explains the two main forces keeping CGC's stock under $1 despite better sales.
Another reverse stock split to protect listing With shares back below $1, Canopy is asking shareholders on Sept. 25 to approve another reverse stock split, after a 2023 split was followed by an 80% drop. A reverse split is a sign the company has no better option and often signals underlying weakness, weighing on sentiment.
A new negative event that directly reflects the stock's listing pressure.

Latest25 Jul – 23 Sep 2026

▲3▼2

Canopy's sales grow but US hopes stall and dilution forces reverse split

Sales growth and shrinking losses Canopy's quarterly revenue rose 13% to C$81.2 million, gross margin improved to 31%, and its adjusted EBITDA loss shrank 59%. Management still targets positive EBITDA this fiscal year. In plain terms, the business is losing less money and selling more, which supports the stock's value.
Shows the fundamental improvement that is the main positive force on CGC.
Debt cut, net cash, medical cannabis growth Canopy finished a major recapitalization that slashed debt and left it with about $131.3 million in net cash. Canadian medical cannabis revenue grew 27% and international medical grew 68%, led by Germany. Less debt and more cash make the company financially safer.
Highlights the balance-sheet repair and medical growth that reduce risk for CGC.
UK medical market entry Canopy signed a supply deal to sell four Canadian-grown medical cannabis strains in the United Kingdom through distributor GROW Group, under its Spectrum Therapeutics brand. This opens a new market for its products, which can add future revenue and supports the stock.
A concrete new distribution deal that expands demand for CGC's products.
US rescheduling stalls and heavy dilution US medical marijuana was rescheduled to Schedule III in April 2026, but broader recreational reforms that would help Canopy USA were left out, so the expected US boost has not materialized. Meanwhile, share count ballooned from 240 million to 423 million, and another $200 million ATM program could dilute holders further. More shares means each existing share is worth less.
Explains the two main forces keeping CGC's stock under $1 despite better sales.
Another reverse stock split to protect listing With shares back below $1, Canopy is asking shareholders on Sept. 25 to approve another reverse stock split, after a 2023 split was followed by an 80% drop. A reverse split is a sign the company has no better option and often signals underlying weakness, weighing on sentiment.
A new negative event that directly reflects the stock's listing pressure.

Sichuan Kelun Pharmaceutical Co Ltd (002422.CS)

Q3 202627 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.

September 202627 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.

Latest27 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.